ATE356873T1 - Antikörper mit verbesserter produzierbarkeit - Google Patents

Antikörper mit verbesserter produzierbarkeit

Info

Publication number
ATE356873T1
ATE356873T1 AT99923439T AT99923439T ATE356873T1 AT E356873 T1 ATE356873 T1 AT E356873T1 AT 99923439 T AT99923439 T AT 99923439T AT 99923439 T AT99923439 T AT 99923439T AT E356873 T1 ATE356873 T1 AT E356873T1
Authority
AT
Austria
Prior art keywords
producability
antibodies
improved
improved producability
Prior art date
Application number
AT99923439T
Other languages
English (en)
Inventor
John Edward Park
Pilar Garin-Chesa
Uwe Bamberger
Wolfgang J Rettig
Olivier Leger
Jose Saldanha
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE356873T1 publication Critical patent/ATE356873T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT99923439T 1998-04-30 1999-04-22 Antikörper mit verbesserter produzierbarkeit ATE356873T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98107925A EP0953639A1 (de) 1998-04-30 1998-04-30 FAPalpha-spezifischer Antikörper mit verbesserter Produzierbarkeit

Publications (1)

Publication Number Publication Date
ATE356873T1 true ATE356873T1 (de) 2007-04-15

Family

ID=8231860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99923439T ATE356873T1 (de) 1998-04-30 1999-04-22 Antikörper mit verbesserter produzierbarkeit

Country Status (27)

Country Link
EP (2) EP0953639A1 (de)
JP (1) JP4421779B2 (de)
KR (1) KR100580936B1 (de)
CN (1) CN1303430A (de)
AR (1) AR016243A1 (de)
AT (1) ATE356873T1 (de)
AU (1) AU760305B2 (de)
BG (1) BG65034B1 (de)
BR (1) BR9910577A (de)
CA (1) CA2327586C (de)
CO (1) CO5050255A1 (de)
DE (1) DE69935516T2 (de)
EA (1) EA005401B1 (de)
EE (1) EE200000642A (de)
ES (1) ES2283114T3 (de)
HU (1) HUP0101501A3 (de)
ID (1) ID26555A (de)
IL (1) IL138701A0 (de)
NO (1) NO20005412L (de)
NZ (1) NZ508456A (de)
PL (1) PL358087A1 (de)
SK (1) SK16192000A3 (de)
TR (1) TR200003181T2 (de)
UA (1) UA73276C2 (de)
WO (1) WO1999057151A2 (de)
YU (1) YU66300A (de)
ZA (1) ZA200005506B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
CA2401252A1 (en) * 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
EP1534331B1 (de) * 2002-06-21 2014-10-29 Johns Hopkins University School of Medicine Membran-assoziierte tumorendothel-marker
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
PL378110A1 (pl) * 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
KR101866623B1 (ko) * 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP1806365A1 (de) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
EP2032159B1 (de) 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
EP2029173B1 (de) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
CN101848936B (zh) * 2007-08-20 2017-05-03 葛兰素集团有限公司 生产方法
EP2071337A1 (de) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase als Krebsmarker
ES2372442T3 (es) * 2007-12-10 2012-01-19 F. Hoffmann-La Roche Ag Seprasa como marcador para cáncer.
WO2009074276A2 (en) * 2007-12-10 2009-06-18 Roche Diagnostics Gmbh Marker panel for colorectal cancer
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PE20171512A1 (es) * 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (de) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
PT3653644T (pt) * 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
CN105646710B (zh) * 2014-11-17 2020-08-25 四川科伦博泰生物医药股份有限公司 一种全人源化抗vegfr-2单克隆抗体及其制备方法
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
AU2017212739B2 (en) * 2016-01-27 2024-03-21 Sutro Biopharma, Inc. Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
EP3478321A4 (de) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotypisierte onkolytische virale verabreichung von therapeutischen polypeptiden
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
CN110526979A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN110526991A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN109053893B (zh) * 2018-08-15 2021-03-30 智享生物(苏州)有限公司 一种抗d-二聚体单克隆抗体及其制备方法
CN112972675A (zh) * 2018-09-07 2021-06-18 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
EP3763726A1 (de) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Verbindungen mit fibroblasten-aktivierendem proteinligand und deren verwendung
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
CN118955620A (zh) 2019-07-08 2024-11-15 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CN117683133A (zh) 2019-09-03 2024-03-12 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
EP4143239A4 (de) * 2020-04-30 2024-10-02 I-Mab Biopharma Co., Ltd. Pharmazeutische zusammensetzungen mit anti-cd47-antikörpern
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
WO2022007283A1 (zh) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
KR102799318B1 (ko) * 2020-08-11 2025-04-23 주식회사 카나프테라퓨틱스 Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
EP4050018A1 (de) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Verbindungen mit fibroblasten-aktivierendem proteinligand und deren verwendung
EP4274835A1 (de) 2021-01-07 2023-11-15 3B Pharmaceuticals GmbH Verbindungen mit einem fibroblastenaktivierungsproteinliganden und verwendung davon
WO2023031644A1 (en) 2021-08-31 2023-03-09 Full-Life Technologies Limited Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof
JP2025503533A (ja) * 2021-12-30 2025-02-04 コンセプト トゥー メディシン バイオテック カンパニー， リミテッド Ｆａｐ－アルファに対するヒト抗体
EP4578877A1 (de) * 2022-08-03 2025-07-02 Nanjing Leads Biolabs Co., Ltd. Antikörperfusionsprotein zum targeting von fap und tgf-beta und verwendung davon
JP2025532754A (ja) 2022-10-07 2025-10-03 ジェネトン 抗ｆａｐ ｃａｒ－ｔ細胞を使用する骨格筋ミオパチーの免疫療法
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN120309735A (zh) * 2024-01-15 2025-07-15 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用
CN118496382B (zh) * 2024-05-22 2025-01-07 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用
CN118812715A (zh) * 2024-07-02 2024-10-22 国睿(广州)生物科技有限公司 一种靶向成纤维活化蛋白α的纳米抗体及其应用
CN119265201A (zh) * 2024-08-23 2025-01-07 中国人民解放军海军军医大学第一附属医院 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU2782292A (en) * 1991-09-18 1993-04-27 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
ZA936260B (en) * 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
EP0859841B1 (de) * 1995-08-18 2002-06-19 MorphoSys AG Protein-/(poly)peptidbibliotheken
CA2248653C (en) * 1996-05-01 2003-08-12 Genitope Corporation Vaccines for treatment of lymphoma and leukemia

Also Published As

Publication number Publication date
UA73276C2 (en) 2005-07-15
EE200000642A (et) 2002-04-15
JP2002513556A (ja) 2002-05-14
PL358087A1 (en) 2004-08-09
EP1098979B1 (de) 2007-03-14
CO5050255A1 (es) 2001-06-27
CA2327586C (en) 2013-02-26
YU66300A (sh) 2004-03-12
EA200001023A1 (ru) 2001-06-25
NZ508456A (en) 2004-03-26
HUP0101501A2 (hu) 2001-08-28
DE69935516T2 (de) 2008-01-31
CA2327586A1 (en) 1999-11-11
EP1098979A2 (de) 2001-05-16
JP4421779B2 (ja) 2010-02-24
EP0953639A1 (de) 1999-11-03
WO1999057151A2 (en) 1999-11-11
AR016243A1 (es) 2001-06-20
BG104828A (en) 2001-09-28
AU4032299A (en) 1999-11-23
NO20005412L (no) 2000-12-06
WO1999057151A3 (en) 2000-03-16
DE69935516D1 (de) 2007-04-26
TR200003181T2 (tr) 2001-04-20
EA005401B1 (ru) 2005-02-24
CN1303430A (zh) 2001-07-11
NO20005412D0 (no) 2000-10-27
BG65034B1 (bg) 2006-12-29
SK16192000A3 (sk) 2001-04-09
AU760305B2 (en) 2003-05-15
ID26555A (id) 2001-01-18
KR100580936B1 (ko) 2006-05-17
ZA200005506B (en) 2002-05-14
IL138701A0 (en) 2001-10-31
HUP0101501A3 (en) 2004-01-28
ES2283114T3 (es) 2007-10-16
BR9910577A (pt) 2001-09-11
KR20010042826A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
DE69935516D1 (de) Antikörper mit verbesserter produzierbarkeit
ID28990A (id) Herbisida-herbisida dengan urea aminofenilsulfonil asilasi
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
ATE341990T1 (de) Sigmidoskop
DE59902874D1 (de) Buchsenkontakt
DE59901560D1 (de) Retrograder tibianagel
DE69937218D1 (de) Verbinder
ID27776A (id) Bahan dengan efek antidepresan
ID30114A (id) Zat-zat herbisida dengan fenoksisulfonilurea tersubstitusi
DE59907306D1 (de) Fadenchangierung
DE59906931D1 (de) Exzenterzahnradgetriebe
DE69920833D1 (de) Verbinder
ATE262513T1 (de) Benzoylpyridazine
DE59903966D1 (de) Exzenterzahnradgetriebe
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59908057D1 (de) Underdruckhandhabungseinrichung
DE59913043D1 (de) Mikroskop mit auflichteinkopplung
DE59808995D1 (de) Endomikroskopsystem
DE59807217D1 (de) Nadellager
DE19842103B4 (de) Stanznietzuführung
ID28905A (id) Antibodi-antibodi dengan afinitas tinggi
NO20005611D0 (no) Gassfölingsinnretning
DE59911463D1 (de) Fahrzeugleitvorrichtung mit Fahrstreckenabtastung
DE59903616D1 (de) Rollenwicklerwalze

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1098979

Country of ref document: EP